Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.26), $0.07 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $6.86 million versus the consensus estimate of $12.56 million.

“In the third quarter, we and our collaborator, Sanofi, have been working diligently with regulatory agencies to make sotagliflozin available for patients with type 1 diabetes as quickly as possible and we continue to make progress in growing XERMELO for its current indication,” said Lonnel Coats, Lexicon’s president and chief executive officer. “Our collaborator, Ipsen, continues to gain approvals and market authorizations for XERMELO in Europe. We are making good progress on our pipeline. By end of year, we expect to start a clinical trial for telotristat ethyl, the investigational form of XERMELO, in biliary tract cancer as well as announce data for LX2761 in diabetes and LX9211, a neuropathic pain candidate, in healthy volunteers.”

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.